← Patent-cliff monitor small molecule SOVALDI SOFOSBUVIR
Loss of exclusivity June 2031 latest FDA-listed patent expiry
Drug detail Brand name SOVALDI Active ingredient SOFOSBUVIR Strength 150MG/PACKET Dosage form PELLETS Route ORAL Modality Small molecule FDA approval August 2019 Marketing status RX
Listed patents Patent Expires Type 8618076*PED June 2031 — 9284342*PED March 2031 — 8618076 December 2030 substance, product 9284342 September 2030 substance, product 8889159*PED September 2029 — 8633309*PED September 2029 — 7964580*PED September 2029 — 8889159 March 2029 product 7964580 March 2029 substance, product 8633309 March 2029 substance, product 8334270*PED September 2028 — 8580765*PED September 2028 — 9085573*PED September 2028 — 8580765 March 2028 substance, product 9085573 March 2028 substance, product 8334270 March 2028 substance, product
Regulatory exclusivity Code Expires ODE-258 August 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.